{"id":"W2978209786","doi":"10.1093/annonc/mdz260.108","title":"Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Ceritinib; Alectinib; Anaplastic lymphoma kinase; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; ALK inhibitor; Surrogate endpoint; Lung cancer; Tolerability; Clinical trial; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00160476,0.001805316,0.002774518,0.0004171912,0.0004744057,0.001807834,0.001112092,0.001345442,0.005017642],"category_scores_gemma":[0.0009885507,0.0007521087,0.003251515,0.0004704744,0.001157211,0.001242961,0.0004285478,0.005864671,0.001567538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001343835,"about_ca_system_score_gemma":0.001632858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0020824,"about_ca_topic_score_gemma":0.006064835,"domain_scores_codex":[0.9996632,0.0001507862,0.00001526948,0.00005442999,0.00002408938,0.00009218633],"domain_scores_gemma":[0.9993454,0.0001139096,0.0001273066,0.00005440423,0.00003655203,0.0003223693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9402145,0.01200219,0.002216454,0.0004408602,0.001740018,0.00009027133,0.0001160442,0.001700864,0.009875239,0.0002580435,0.002991748,0.0283538],"study_design_scores_gemma":[0.8459512,0.1394793,0.007862151,0.00004387707,0.001129252,0.0001657387,0.00008121145,0.001458836,0.001189652,0.0003586196,0.002243002,0.00003714573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873729,0.003729269,0.0004679744,0.001302648,0.0004608918,0.00129608,0.002233857,0.0002064009,0.00292984],"genre_scores_gemma":[0.98507,0.002592225,0.001318812,0.001746135,0.0002952644,0.00148409,0.003668923,0.00006694045,0.003757654],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005017642,"threshold_uncertainty_score":0.01678568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02589946100375657,"score_gpt":0.3862981845905549,"score_spread":0.3603987235867984,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}